Kalaris (NASDAQ:KLRS) reported its fourth-quarter and full-year 2025 financial results today, delivering a clinical update that positions its lead candidate as a potential disruptor in the $13 billion anti-VEGF market.
The company’s Phase 1a study evaluating its next-generation therapy for neovascular age-related macular degeneration (nAMD) met its primary safety and efficacy goals.
Data showed a mean improvement of 10 letters in Best Corrected Visual Acuity (BCVA) and a mean reduction in Central Subfield Thickness (CST) of 129μm.
Beyond basic vision gains, the therapy achieved a staggering 95% reduction in intraretinal fluid, a key marker for disease activity.
Most notably, the drug demonstrated a highly localized effect; plasma Cmax levels (the peak concentration of the drug in the bloodstream) were 27 to 51 times lower than those of currently leading anti-VEGF agents.
This suggests a significantly reduced risk of systemic side effects, which has been a lingering concern for the aging patient population receiving frequent intravitreal injections.
Financially, Kalaris successfully fortified its balance sheet to support the transition into mid-stage clinical trials.
The company completed a $50 million private placement, bringing its total cash and marketable securities to $118 million as of December 31, 2025.
While the company reported a net loss of $43.4 million for the year—driven by the heavy clinical and manufacturing ramp-up—management expects its current capital to fund operations into the fourth quarter of 2027.
Looking toward 2026, Kalaris is preparing to initiate its Phase 2 "head-to-head" study against current standard-of-care treatments.
The goal is to prove that its therapy not only matches the efficacy of existing drugs but offers a superior safety profile and longer durability, potentially reducing the burden of frequent eye injections.